GRAFORCE
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Kawasaki Gas Turbine Europe GmbH (Kawasaki), a European gas turbine and heat-power cogeneration business, are cooperating for zero-emission heat and power generation. The joint innovative plant concept combines Graforce's methane electrolysis technology (plasmalysis) with hydrogen turbines from Kawasaki. First customer projects for this zero carbon heat and power solution are in the works.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005010/en/
Hydrogen turbines and methane electrolysis are game changers for an electricity-independent zero carbon heat-power cogeneration. (Photo: Business Wire)
“Our joint zero-emission plant is a breakthrough for the decarbonization of both, fossil fuels and manufacturing industries”, explains Dr. Jens Hanke, CTO of Graforce. “This technology generates CO2-free high-temperature heat via hydrogen, the carbon black is used as a raw material in production, and – best of all, the process is self-sufficient and does not need further electricity after having been started. This in turn relieves the strain on power grids.”
Decarbonization of industrial processes
The new plant solution generates hydrogen from biomethane, natural gas, LNG or LPG by methane electrolysis technology. The hydrocarbons will remain the initial source, but instead of being burnt, a high frequency plasma splits the hydrocarbons into CO2-free hydrogen and carbon black.
The hydrogen is converted to electricity in Kawasaki's hydrogen gas turbine and reused for hydrogen production in the plasma electrolyzer. The ultra-high temperature CO2-free exhaust gas from the hydrogen gas turbine can be used in production processes in various industries. Companies that previously generated high-temperature heat with natural gas can significantly increase their overall efficiency while reducing their gas and especially electricity costs.
Carbon black is used as a synthetic raw material for industrial production. This way, CO2 can be sequestered long-term in steel, cement or for soil enhancement. For industries which require both high temperatures and large quantities of carbon black for production this process pays off twice – in terms of climate protection and cost-effectiveness.
Beyond industry, this hydrogen-based heat-power cogeneration plant can be used for CO2-free heating in surrounding urban areas.
Both technologies were awarded with the Innovation Award of the German Gas Industry, in 2020 and 2022.
About
Kawasaki Gas Turbine Europe GmbH
The German company, 100% subsidiary of Kawasaki Heavy Industries, LTD. (Japan), providing natural gas and hydrogen gas turbine generator set to improve the energy efficiency for various industries and to contribute the global environmental conservation. http://www.kawasaki-gasturbine.de/en
Graforce GmbH
Graforce is German hydrogen technology company developing and manufacturing Power-to-X plants to decarbonize fossil energies, industrial sectors and the heat, transport and building sectors. The company is currently in a process to expand its strategic partnerships with financial as well as strategic investors to quickly scale its hydrogen technology worldwide. www.graforce.com/EN
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release
Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release
Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)17.9.2025 21:46:00 CEST | Press release
Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commission’s approval of vimseltinib for TGCT is a significant milestone for Deciphera, ONO, and TGCT patients across the European Union who are in need of a non-invasive treatment option. We are excited to leverage our global commercial infrastructure to bring vimseltinib to these patients,” said Ryota Udagawa, President and Chief Executive Officer of Deciphera. “We look forward to worki
Northern Escape Heli-Skiing Sees Global Surge in Demand as Adventurers Seek Canada’s Legendary Powder17.9.2025 18:09:00 CEST | Press release
Luxury adventure travel continues accelerating, with analysts projecting ~7.6% annual growth through 2030 [1][5]. Meanwhile, global tourism reached record highs in 2024 [2], and ski tourism is above pre-pandemic norms [3]. Northern Escape Heli-Skiing (NEH), named World’s Best Heli-Ski Operator by the World Ski Awards [4] in 2022, 2023, and 2024, continues to welcome a truly international mix of guests each winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909723150/en/ Global Appeal Post-pandemic travellers prioritize remote, nature-led adventures and privacy-forward itineraries [1][3]. Adventure tourism is on a sharp upswing globally [5], while research highlights how social media and influencer content accelerate demand for marquee mountain experiences [7]. At the same time, heli-sports are forecast to expand steadily across Canada, Europe, APAC, and South America [8]. World’s Best Heli-Ski NEH operates in BC’s Ske
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom